SCHEMBL6432447

SCHEMBL6432447

COC(=O)c1cccc(-c2cccc(OC)c2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NEK1 Q96PY6 1/20 0.63
SMN1; SMN2 Q16637 4/20 0.61
TP53 P04637 2/20 0.61
PLAU P00749 3/20 0.60
PLAT P00750 2/20 0.60
PLG P00747 1/20 0.60
HSD17B2 P37059 1/20 0.60
MAPT P10636 1/20 0.58
CES2 O00748 1/20 0.58
CES1 P23141 1/20 0.58
MEN1 O00255 2/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
KMT2A Q03164 2/20 0.57
CA12 O43570 1/20 0.57
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
CA9 Q16790 1/20 0.57
ALDH1A1 P00352 1/20 0.57
PKM P14618 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8440880 0.92 CYP1A1 (0.61) NEK1SMN1; SMN2TP53PLAUPLAT
Methyl 3-Methoxybenzoate SCHEMBL384913 0.89 SMN1; SMN2 (0.73) SMN1; SMN2TP53MAPTCES2CES1
Methyl 3-Methoxybenzoate SCHEMBL29702092 0.89 SMN1; SMN2 (0.73) SMN1; SMN2TP53MAPTCES2CES1
SCHEMBL67941 0.89 CA12 (0.68) PLAURAB9ACA12CA1CA2
SCHEMBL6716525 0.88 PLAU (0.60) SMN1; SMN2TP53PLAUPLATPLG
SCHEMBL7825137 0.88 PLAU (0.66) SMN1; SMN2PLAUPLATPLGMEN1
SCHEMBL1179594 0.87 PLAU (0.73) PLAUPLATPLGHSD17B2CA12
SCHEMBL27715902 0.87 CA12 (0.71) PLAUPLATPLGCA12CA1
SCHEMBL28493230 0.87 KDM4E (0.58) NEK1SMN1; SMN2TP53PLAUPLAT
SCHEMBL14898342 0.85 ERN1 (0.54) NEK1SMN1; SMN2TP53PLAUPLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1087943-B1 THERAPEUTIC BIARYL DERIVATIVES GLAXO GROUP LTD (GB) 2005-08-17 EP disclosed
CN-1080257-C Guanidine derivatives as inhibitors of Na+/H+ exchange in cells FUJISAWA PHARMACEUTICAL CO (JP) 2002-03-06 CN disclosed
EP-0699185-B1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO (JP) 2001-09-05 EP disclosed
US-6251925-B1 AN AGONISTS FOR HUMAN BETA-3 ADRENOCEPTOR GLAXO WELLCOME INC. 2001-06-26 US disclosed
EP-1087943-A1 THERAPEUTIC BIARYL DERIVATIVES GLAXO GROUP LIMITED (GB) 2001-04-04 EP disclosed
WO-1999065877-A1 THERAPEUTIC BIARYL DERIVATIVES GLAXO GROUP LIMITED (GB) 1999-12-23 WO disclosed
US-5824691-A CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-10-20 US disclosed
CN-1123545-A Guanidine derivatives as inhibitors of Na+/H+ exchange in cells FUJISAWA PHARMACEUTICAL CO (JP) 1996-05-29 CN disclosed
EP-0699185-A1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-03-06 EP disclosed
WO-1994026709-A1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-11-24 WO disclosed